Conference
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).
Abstract
5551
Background: Genomic characterization of mCRPC has identified commonly occurring alterations but also recurrently mutated genes at much lower frequencies. To efficiently evaluate anti-tumor activity of novel targeted therapies in mCRPC patients (pts) we initiated an umbrella trial using circulating tumour DNA (ctDNA) to enrich accrual for cancers with alterations that may predict response. Methods: mCRPC pts that have …
Authors
Chi KN; Mukherjee S; Saad F; Winquist E; Ong M; Kolinsky MP; Sacher AG; Ferrario C; Salim M; Macfarlane RJ
Volume
38
Pagination
pp. 5551-5551
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2020
DOI
10.1200/jco.2020.38.15_suppl.5551
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X